Cipla (CIPLA) — Financial Results

Cipla reported FY25 consolidated revenue of ₹27,548 crores, up 8% YoY, with PAT at ₹5,273 crores, up 28% YoY, driven by 7% growth in One India and strong performance across North America, Africa, and emerging markets. EBITDA margin expanded to 25.9% from 24.5% as operational efficiencies and mix improvements boosted profitability. Net cash stood at ₹10,369 crores, supporting strategic investments and shareholder returns.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this financial results affect Cipla Limited's outlook?" "What did Cipla Limited announce on 13 May 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 13 May 2025

SHRIRAMFIN Shriram Finance Limited Announcement TATASTEEL Tata Steel Limited Financial Results SRF SRF Limited Financial Results SRF SRF Limited Financial Results SRF SRF Limited Financial Results TITAN Titan Company Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.